SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Eagle Pharmaceuticals, Inc. (EGRX) trades at a trailing P/E of 0.0. Trailing earnings yield is 3,333.33%.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (0.0); earnings yield beats bond yields (3,333.33%).
- Trailing Earnings Yield 3,333.33% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 72/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EGRX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$2.73
Book Value / Share$0.00
Revenue / Share$24.23
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3,333.33%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.57 |
$13.68M |
$-6.05M |
-44.2% |
| 2014 |
$-1.81 |
$19.1M |
$-17.98M |
-94.1% |
| 2015 |
$0.16 |
$66.23M |
$2.57M |
3.9% |
| 2016 |
$4.96 |
$189.48M |
$81.45M |
43% |
| 2017 |
$3.27 |
$236.71M |
$51.94M |
21.9% |
| 2018 |
$2.09 |
$213.31M |
$31.9M |
15% |
| 2019 |
$1.01 |
$195.89M |
$14.31M |
7.3% |
| 2020 |
$0.87 |
$187.8M |
$11.99M |
6.4% |
| 2021 |
$-0.66 |
$171.55M |
$-8.63M |
-5% |
| 2022 |
$2.73 |
$316.61M |
$35.64M |
11.3% |
